Clinical Trials
8 trialsNCT04280081 2026-04-24
LIBRETTO-321
Eli Lilly and Company
Phase 2 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT04211337 2026-03-19
LIBRETTO-531
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04819100 2026-03-04
LIBRETTO-432
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT04194944 2025-10-21
LIBRETTO-431
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03944772 2025-01-30
ORCHARD
AstraZeneca
Phase 2 Active not recruiting
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing